Sargent Investment Group’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
VCM
VPM
Sargent Investment Group's BMY Position: Q1 2026 in Review
Sargent Investment Group increased its Bristol-Myers Squibb (BMY) stake by 16% in Q1 2026, buying an estimated $291K and bringing the position to 35,930 shares worth $2.18M. The position accounts for 0.29% of the portfolio, ranked #70.
Sargent Investment Group first reported a position in BMY in Q3 2020 and has held it in 21 quarters since. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Sargent Investment Group held 35,930 shares of Bristol-Myers Squibb worth $2.18M as of Q1 2026.
- Sargent Investment Group bought 4,996 Bristol-Myers Squibb shares in Q1 2026, an estimated $291K.
- Bristol-Myers Squibb made up 0.29% of Sargent Investment Group's portfolio in Q1 2026, its #70 holding.
- Sargent Investment Group first reported a position in Bristol-Myers Squibb in Q3 2020 and has held it in 21 quarters since.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Sargent Investment Group's 13F filing for Q1 2026, filed 11 May 2026.